Nuvalent, Inc.
zidesamtinib
ROS1-positive solid tumors
Resolved
35days ago
Phase 1 readout · ~ Jun 2, 2026 estimated
What's at stake
Phase 1 trial results for zidesamtinib in ROS1-positive solid tumors are due ~ Jun 2, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“The company also plans to present preliminary data from the ongoing ARROS-1 Phase 1/2 clinical trial of zidesamtinib ... during a poster session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 – June 2, 2”